189 related articles for article (PubMed ID: 31546071)
1. Identification of the BRAF V600E mutation in a patient with sclerosing pneumocytoma: A case report.
Jiang G; Zhang M; Tan Q; Lin S; Zeng Y; Liu C; Chen R; Zhou J
Lung Cancer; 2019 Nov; 137():52-55. PubMed ID: 31546071
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary sclerosing pneumocytoma masquerading adenocarcinoma with co-existing BRAF V600E and PTEN mutation.
Dantis K; Gupta AK; Kashyap NK; Kashyap Y; Ranganath TG; Pati SK; Kumar M; Thakur S; Ravina M
Cancer Treat Res Commun; 2021; 28():100429. PubMed ID: 34246179
[TBL] [Abstract][Full Text] [Related]
3. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma.
Yeh YC; Ho HL; Wu YC; Pan CC; Wang YC; Chou TY
Mod Pathol; 2020 Mar; 33(3):391-403. PubMed ID: 31527710
[TBL] [Abstract][Full Text] [Related]
4. Coexistence of glandular papilloma and sclerosing pneumocytoma in the bronchiole.
Kitawaki Y; Fujishima F; Taniuchi S; Saito R; Nakamura Y; Sato R; Aoyama Y; Onodera Y; Inoshita N; Matsuda Y; Watanabe M; Sasano H
Pathol Int; 2018 Jul; 68(7):425-430. PubMed ID: 29696743
[TBL] [Abstract][Full Text] [Related]
5. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Metastatic and Nonmetastatic Pulmonary Sclerosing Pneumocytomas: A Clinicopathological Study of 68 Cases and 15 Reported Metastatic Cases.
Wang X; Ng CS; Shi X; Yin W
Lab Invest; 2023 Jul; 103(7):100135. PubMed ID: 36966952
[TBL] [Abstract][Full Text] [Related]
7. Adult classical glioblastoma with a BRAF V600E mutation.
Takahashi Y; Akahane T; Sawada T; Ikeda H; Tempaku A; Yamauchi S; Nishihara H; Tanaka S; Nitta K; Ide W; Hashimoto I; Kamada H
World J Surg Oncol; 2015 Mar; 13():100. PubMed ID: 25885250
[TBL] [Abstract][Full Text] [Related]
8. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics.
Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z
Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics.
Karamzadeh Dashti N; Bahrami A; Lee SJ; Jenkins SM; Rodriguez FJ; Folpe AL; Boland JM
Am J Surg Pathol; 2017 Nov; 41(11):1532-1541. PubMed ID: 28834810
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic and Transcriptomic Analysis of Sclerosing Pneumocytoma.
Yeh YC; Chu PY; Lin SY; Wang SY; Ho HL; Wang YC
Mod Pathol; 2024 Jan; 37(1):100354. PubMed ID: 37844870
[TBL] [Abstract][Full Text] [Related]
11. Genome profile in a extremely rare case of pulmonary sclerosing pneumocytoma presenting with diffusely-scattered nodules in the right lung.
Fan X; Lin L; Wang J; Wang Y; Feng A; Nie L; Wu H; Meng F; Xu H
Cancer Biol Ther; 2018 Jan; 19(1):13-19. PubMed ID: 29236566
[TBL] [Abstract][Full Text] [Related]
12. Negative reactions of BRAF mutation-specific immunohistochemistry to non-V600E mutations of BRAF.
Seto K; Haneda M; Masago K; Fujita S; Kato S; Sasaki E; Hosoda W; Murakami Y; Kuroda H; Horio Y; Hida T; Okubo K; Yatabe Y
Pathol Int; 2020 May; 70(5):253-261. PubMed ID: 31970865
[TBL] [Abstract][Full Text] [Related]
13. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
[TBL] [Abstract][Full Text] [Related]
14. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
[TBL] [Abstract][Full Text] [Related]
17. ["Pneumocytoma" or "sclerosing hemangioma": histogenetic aspects of a rare tumor of the lung].
Einsfelder BM; Müller KM
Pathologe; 2005 Sep; 26(5):367-77. PubMed ID: 15731902
[TBL] [Abstract][Full Text] [Related]
18. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
19. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
[No Abstract] [Full Text] [Related]
20. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
